P-Rex proteins are Rho/Rac guanine nucleotide exchange factors which participate in the regulation of several cancer-related cellular functions such as proliferation, motility and invasion. Expectedly, significant part of these actions of P-Rex proteins must be related to their Rac regulatory properties. In addition P-Rex proteins control signaling by the PI3K route by interacting with PTEN and mTOR. The interaction with PTEN inhibits its phosphatase activity, leading to AKT activation. The interaction with mTOR may be important in nutrientstimulated Rac activation and migration. In humans, several studies have implicated P-Rex proteins in the pathophysiology of various neoplasias. Thus, overexpression of P-Rex proteins has been linked to poor patient outcome in breast cancer, and may facilitate metastatic dissemination of prostate cancer cells. In addition, whole genome sequencing described PRex2 as a significantly mutated gene in melanoma. Furthermore, expression in melanocytes of mutated forms of P-Rex2 found in melanoma patients demonstrated the protumorigenic role of these P-Rex mutations in melanoma genesis. These evidences open interesting opportunities for P-Rex targeting in cancer. Moreover, the implication of P-Rex partner proteins such as Rac, mTOR or PTEN in cancer has opened the possibility of acting on P-Rex to restrict protumorigenic signaling through these pathways.
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Physiological relevance of P-Rex proteins.
P-Rex1 is mainly expressed in peripheral blood leukocytes and brain, and is also expressed in several other tissues (8, (11) (12) (13) (14) . P-Rex2 is widely expressed, and is strongly present in skeletal muscle, small intestine, heart, lung and placenta, being absent from peripheral blood leukocytes (10, 11, 13) .
P-Rex1
-/-mice are viable and apparently healthy, but have mild neutrophilia (15) . In the neutrophils of these mice the G protein coupled receptor (GPCR)-dependent Rac activation and recruitment to inflammatory sites was impaired (15, 16) . In leukocytes, P-Rex1 has been involved in integrin-mediated rolling and intravascular crawling (17) . In lung microvascular endothelial cells, P-Rex1 participated in TNF-α-stimulated Rac activation and ROS production (18). Removal of P-Rex1 significantly reduced neutrophilic transendothelial migration and leukocyte sequestration in TNF-α-challenged mouse lungs. The P-Rex1 knockout mice were also refractory to lung vascular hyper-permeability and edema in a LPSinduced sepsis model. P-Rex2b also appears to be relevant in the regulation of Rac1 activation and cell migration of endothelial cells (19) .
P-Rex proteins are widely expressed in the nervous system (13) , and have been involved in neuronal migration (14) , differentiation (7) , and memory-related functions (20) .
Transfection of P-Rex1 inhibited neurite sprouting in PC12 cells (7) . Moreover, expression of an N-terminal truncated form of P-Rex had the same action as full length P-Rex1, suggesting that the neurite-regulating functions of P-Rex1 may be partially independent of its Rac regulatory properties (7) . On the other hand, expression of a mutant lacking the DH domain, which acts as a dominant negative form with respect to the GEF activity of P-Rex1, decreased neuronal migration induced by neurotrophic factors (14) . With respect to P-Rex2, mice
Research. lacking the PREX2 gene are viable and fertile, but develop a mild motor coordination defect and have alterations of the Purkinje cell dendrite morphology (13) .
Together, these studies demonstrate the non-redundant functions of P-Rex proteins in animal physiology. This is relevant if one considers the large complement of Rac GEF factors reported which are also widely expressed (21) .
Regulation of P-Rex proteins.
The activation of P-Rex is directly and synergistically produced by the binding of PIP3 to the PH domain, and the Gβγ subunits to the DH domain (8, 22, 23) (Figure 1B ). These bindings favor translocation of P-Rex from the cytosol to the plasma membrane, where P-Rex GEF activity is higher (8, 23) . Deletion studies indicated that the DH/PH domains are sufficient to activate P-Rex by PIP3 (22) . The other domains (two DEP, two PDZ and IP4P) keep the catalytic activity of full-length P-Rex1 low (22) , suggesting that interactions between the DH/PH domains and the other domains may autoinhibit P-Rex activity.
Phosphorylation of P-Rex represents an important mechanism of regulation of its function. Several reports have indicated that P-Rex1 is phosphorylated at multiple sites (9, 24, 25) , and the phosphorylation of these sites regulates P-Rex1 activity in an opposite fashion. In breast cancer cells, phosphorylation of Ser 313 and Ser 319 , located in the PH domain, inhibits PRex1 activity under resting conditions and mutation to non-phosphorylatable residues augments Rac activity (9) . Stimulation of ErbB receptors, which increases Rac activity in those cells, was accompanied by dephosphorylation of Ser 313 and Ser 319 (9) . Interestingly, β-adrenergic receptor activation increases the phosphorylation of P-Rex1, likely through PKA, and such a phosphorylation diminishes P-Rex1 GEF activity (24) . Moreover, dephosphorylation of P-Rex1 by λ-phosphatase (24) or protein phosphatase 1α (PP1α) (25) Research. increases the activity of P-Rex1. In aggregate, these reports support the concept that phosphorylation of P-Rex1 at certain residues inhibits its GEF activity towards Rac. The PI3K/mTOR route and P-Rex proteins.
Of particular relevance is the interplay among the phosphoinositide 3-kinase (PI3K) route and P-Rex proteins. P-Rex1 was initially described as a Rac GEF up-modulated by the βγ subunits of heterotrimeric G proteins and by PIP3, which is generated by PI3K (8) . P-Rex proteins interact with mTOR and PTEN, two important players in PI3K signal transduction (5, 6) . The interaction of P-Rex1 and P-Rex2 with mTOR occurs through the DEP domains of the P-Rex proteins, and regulates nutrient-stimulated Rac activation and cell migration (6) . independent on the GEF activity of P-Rex2a. In MCF10A cells which express endogenous active PTEN, forced expression of P-Rex2a augmented AKT phosphorylation at serine 473, and favored the formation of multiacinar structures (5), a feature that in these cells has been associated to a pretumorigenic status (27) . In ovarian cancer cells expression of P-Rex1 has been shown to promote activation of AKT1 and P-Rex1 knockdown inhibited AKT1 (28) .
CLINICAL-TRANSLATIONAL ADVANCES
Several circumstances indicate that P-Rex proteins may play a role in the pathophysiology of various neoplastic diseases. On one hand, P-Rex expression levels have been shown to correlate with patient outcome in several neoplasias. Moreover, molecular alterations of P-Rex have been described in melanoma, and some of these alterations promote tumorogenesis. On the other hand, P-Rex proteins have been shown to participate in the regulation of several prooncogenic properties such as migration, cell proliferation, or invasion. These clinicopathological and biological findings open the possibility of targeting P-Rex proteins with therapeutic purposes. Moreover, the implication of P-Rex partner proteins such as Rac, mTOR or PTEN in cancer offers the possibility of acting on P-Rex to restrict protumorigenic signaling through these pathways.
Expression and molecular alterations of P-Rex proteins in cancer.
Studies in breast (9, 29) and prostate cancer (30) demonstrated a link between P-Rex expression and patient outcome. Sosa et al. found that >50% of breast tumors stained for PRex1 (29) . Normal breast tissue and the stroma did not stain for P-Rex1. P-Rex1 staining was higher in patients with metastatic disease, suggesting a role of P-Rex1 in metastatic dissemination. Montero et al analyzed P-Rex expression in breast tumors by quantitative Western blotting (9) . Expression of P-Rex was found to be variable among different patient These mutations were distributed along the entire length of P-Rex2, and included nonsynonymous PREX2 mutations as well as truncations (36) . Biological experiments in which some of the P-Rex2 mutations found in patients were reproduced in TERT-immortalized human melanocytes demonstrated the role of this GEF in melanoma genesis, and demonstrated that PREX2 mutations generate altered proteins with oncogenic activity (36) .
Prometastatic properties of P-Rex.
In prostate cancer cell lines and human samples expression of P-Rex1 strongly correlated with the metastatic phenotype (30). Qin et al (30) reported that P-Rex1 acted through Rac to facilitate migration and invasion of prostate cancer cells upon activation of the epidermal growth factor receptor. Moreover, overexpression of P-Rex1 in a non-metastatic 
cell line increased its motility and invasion properties. In their prostate cancer models, P-Rex1 did not affect prostate tumor growth, but caused spontaneous lymph node metastases.
Similarly, in ovarian cancer cells knockdown of P-Rex1 inhibited insulin-like growth factor-1 (IGF-1)-induced activation of cell migration or invasion (28) . In breast cancer cells, activation of ErbB or chemokine receptors facilitated cellular migration in a P-Rex dependent manner (9, 29) .
In the skin, Lindsay et al. showed that P-Rex1 was required for efficient melanoblast migration and melanoma dissemination (37) . Using an animal model of melanoma, which included mutant N-Ras as well as deletion of the INK4a tumor suppressor, the authors described decreased melanoma metastases when these mice were crossed with P-Rex1 -/-mice (37) . Interestingly, no differences in tumor latency or burden in the primary melanomas were observed when P-Rex +/+ mice and P-Rex -/-mice were compared. In line with these data Campbell et at (38) reported that P-Rex1 favored the invasiveness of WM852 melanoma cells. Therefore, targeting of P-Rex1 in prostate, ovarian, breast or skin cancer may be beneficial in fighting disease dissemination.
Role of P-Rex proteins in proliferation.
While Mechanistically, it will be important to define whether RTKs and other cell surface receptors activate P-Rex by the same mechanism used by the ErbB receptors, i.e. by activating the P-Rex phosphorylation/dephosphorylation cycle. It will also be relevant to 
identify the kinases and phosphatases involved in controlling that cycle, and the signaling cascades which mediate activation of those kinases and phosphatases. Finally, elucidation of additional P-Rex-interacting proteins could help in understanding the protein networks in which P-Rex proteins participate.
Targeting P-Rex in cancer.
Given the ample number of Rac GEFs (21), we may consider unreasonable to target PRex proteins. However, clinicopathological as well as preclinical data support roles of P-Rex proteins in human cancer, opening therapeutic options for the targeting of P-Rex proteins in cancer. In fact, P-Rex expression has been correlated with patient outcome in breast and prostate cancers, and reduction of P-Rex expression has been shown to restrict proliferation and/or metastatic dissemination (9, 29, 30) . Therefore, targeting P-Rex proteins may be therapeutically relevant in neoplasias in which those proteins play an important role in regulating their growth or dissemination.
Of particular relevance is the role of P-Rex proteins in melanoma pathophysiology. The fact that mutated forms of P-Rex2 have been detected in melanoma and are tumorigenic (36) , raises the possibility of targeting P-Rex2 in melanomas bearing such mutations. Moreover, Lindsay et al demonstrated that P-Rex1 was required for efficient melanoblast migration and melanoma dissemination (37) . Interestingly, expression of P-Rex1 in melanoma cell lines has been reported to be controlled by the ERK route (40) . This is relevant given the high frequency of activation of the ERK pathway in melanomas due to upstream mutations in BRAF (36) . It is possible that BRAF inhibitors used in the clinic, such as vemurafenib (41), or other BRAF/ERK pathway inhibitors may reduce P-Rex1 levels and therefore contribute to preventing P-Rex1-facilitated melanoma dissemination.
Besides controlling P-Rex proteins by down regulating their cellular levels, another way of acting on these proteins may be the use of strategies which affect their functionality. Such In addition to the above mentioned strategies which directly target P-Rex proteins, indirect ways to reduce P-Rex signaling may be contemplated. These strategies rely on the use of drugs that act on signaling proteins upstream or downstream of P-Rex, such as inhibitors of RTKs, GPCRs, Rac, or dual PI3K/mTOR inhibitors. It is expected that increasing the knowledge about the regulatory mechanisms responsible for controlling P-Rex functioning may allow the development of additional strategies. As an example, augmenting the phosphorylation of P-Rex1 at inhibitory residues may also be exploited to reduce its functionality. This would require unveiling the kinases and phosphatases responsible for maintaining P-Rex in its "off" state ( Figure 1B ).
In conclusion, the ample range of physiological cancer-related functions of P-Rex, 
